A phase III clinical trial of the 6-month formulation of leuprorelin in patients with prostate cancer.
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2015
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- 30 Oct 2015 According to a Takeda media release, the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application for Leuprorelin (Leuplin) for the treatment of prostate cancer and premenopausal breast cancer.
- 01 Mar 2012 New trial record